Interestingly, both ponatinib and cabozantinib were included in the BEAT AML study, where both acted more efficacious in FLT3-ITD+ samples compared to FLT3-ITD− (Figure S1E) [25]. Here, FLT3 is linked to acute myeloid leukemia.